NEWS

Ibex Obtains CE-IVD Mark for AI-powered Cancer Detection

February 27, 2020

Ibex’s Galen™ Prostate solution demonstrates outstanding results in a blinded study and supports pathologists in providing accurate diagnosis, enhanced lab efficiency and quality control.

Read More

Karius raises $165 million for its liquid biopsy technology identifying diseases with a blood draw

February 24, 2020

While the new money may have been raised under the looming threat of Covid 19, the company’s technology is already being used to test for infection-causing pathogens in immunocompromised pediatric patients, and for potential causes of complex pneumonia, fungal infections and endocarditis, according to a statement from the company.

Read More

Interview: Healthtech Is Israel’s Next Growth Engine, Says Venture Capitalist

February 21, 2020

Yair Schindel was a decorated army medic, a doctor, an entrepreneur, and the head of Israel’s National Digital Bureau. Now, he manages Israeli venture capital fund aMoon and wants to turn Israel into a healthtech empire.

Read More

Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company

December 24, 2019

Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts, aMoon told Calcalist. This is NanoGhosts’s first investment.

Read More

Seer Announces $55 Million in Series D Equity Financing Bringing in New Investors aMoon Fund and T. Rowe Price Funds

December 19, 2019

Capital will enable continued advancement of novel Proteograph™ platform and commercialization of first-in-class proteomics products

Read More

Newly Merged Voice Analysis Startups Healthymize and Beyond Verbal Raise $9 Million

December 10, 2019

The new entity, Vocalis Health, will develop technology for the voice-based analysis and detection of health issues such as heart and respiratory conditions and depression

Read More

Steven Mnuchin, Israeli Health Officials Discuss Establishment of Israeli FDA Branch

October 29, 2019

The FDA, which approves all medical devices and formulations in the U.S., has very few branches outside of the U.S.

Read More

aMoon invests in $80m Adicet Bio financing round

October 3, 2019

Based on technology developed by the Technion’s Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

Read More

MDClone, Developer of First Healthcare Synthetic Data Engine, Raises $26 Million

August 22, 2019

aMoon Leads New Investment Round with Participation from OrbiMed and Lightspeed Venture Partners.

Read More

Israel’s 10 ‘Hottest’ Startups In 2019, According to WIRED Magazine

August 21, 2019

Tel Aviv – has “the highest number of startups per capita in the world…with more than 6,000, of which 18 are unicorns…more than 100 venture capital funds, plus hundreds of accelerators and co-working places.”

Read More

Israel’s Largest Health VC Boosts Fund to $750 Million on Virus

July 22, 2020

Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.

Read More

Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics

July 15, 2020

Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.

Read More

Israel Bolsters Antibody Tests as Second Virus Wave Threatens

July 3, 2020

Israel is fortifying its national survey of exposure to the coronavirus as a second wave of infections threatens to plunge the country back into lockdown.

Read More

‘Covid Put Everything On Steroids,’ Says Prominent Healthtech Investor

June 30, 2020

When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner.

Read More

NIH Partners with Israeli Startup to Generate Synthetic COVID-19 Data

June 18, 2020

Through a new partnership, the National Institutes of Health will harness Israeli startup MDClone’s platform to generate computationally-derived synthetic data directly from clinical health data aggregated across the U.S., to underpin and advance research in the fight against COVID-19.

Read More

Curesponse Secures $6M Series A for Breakthrough Precision Medicine

June 5, 2020

Curesponse, a cancer precision medicine company, has raised $6M from investors including NCL Technology Ventures (UK) and aMoon (Israel) for scaling clinical trials and international expansion to the UK.

Read More

Zebra Medical Vision Secures its 5th FDA Clearance, Making Its Vertebral Compression Fractures AI Solution Available in the U.S.

May 18, 2020

Zebra Medical Vision, the deep-learning medical imaging analytics company, announces today its fifth FDA 510(k) clearance for its Vertebral Compression Fractures (VCF) product.

Read More

Ayala Pharmaceuticals Announces Pricing of Initial Public Offering

May 7, 2020

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.

Read More

Herd Immunity, or Big 2nd Wave? Israel Antibody Testing Hopes to Find Out

May 5, 2020

Yair Schindel, aMoon Managing Partner and a member of Israel’s health ministry task force on COVID-19, spoke to the The New York Times about the pandemic and Israel’s latest initiative to conduct nationwide serological testing on 100,000 citizens. Yair outlined the two likely scenarios Israel might find out as a result of the antibody testing.

Read More

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

April 29, 2020

resTORbio, Inc. (Nasdaq: TORC) and Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications.

Read More